icon-folder.gif   Conference Reports for NATAP  
  The International Liver Congress™
EASL 2017 - European Association for the
Study of the Liver
Amsterdam, The Netherlands. 2017
Back grey_arrow_rt.gif
Elbasvir/Grazoprevir Plus Sofosbuvir ± Ribavirin in Treatment-Naive And Treatment-Experienced People With Hepatitis C Virus Genotype 3 Infection and Compensated Cirrhosis: SVR24 Results of the C-ISLE Study
  Reported by Jules Levin
EASL 2017
The International Liver
Congress™ 2017;
April 19-23, 2017;
Amsterdam, The Netherlands
Foster GR1; Agarwal K2; Cramp M3; Moreea S4; Barclay S5; Collier J6; Brown AS7; Ryder SD8; Ustianowski A9; Forton DM10; Fox R11; Gordon F12; Rosenberg WM13; Mutimer DJ14; Du J15; Gilbert CL15; Robertson MN15; Barr E15; Haber B15 1The Royal London Hospital, London, UK; 2Institute of Liver Studies, Kings College Hospital, London, UK; 3South West Liver Unit, Derriford Hospital and Peninsula School of Medicine and Dentistry, Plymouth, UK; 4Bradford Teaching Hospitals Foundation Trust, Bradford, UK; 5Glasgow Royal Campus, Glasgow, UK; 6John Radcliffe Hospital, Oxford, UK; 7Imperial College Healthcare, London, UK; 8NIHR Biomedical Unit in Gastrointestinal and Liver Diseases at Nottingham University Hospitals NHS Trust and The University of Nottingham, Nottingham, UK; 9North Manchester General Hospital, Manchester, UK; 10St. Georges University of London, London, UK; 11Gartnavel General Hospital, Glasgow, UK; 12Hepatology Joint Clinical Research Unit, Bristol, UK; 13University College London, London, UK; 14QE Hospital, Birmingham, UK; 15Merck & Co., Inc., Kenilworth, NJ, USA